PE20080992A1 - Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c - Google Patents

Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c

Info

Publication number
PE20080992A1
PE20080992A1 PE2007000815A PE2007000815A PE20080992A1 PE 20080992 A1 PE20080992 A1 PE 20080992A1 PE 2007000815 A PE2007000815 A PE 2007000815A PE 2007000815 A PE2007000815 A PE 2007000815A PE 20080992 A1 PE20080992 A1 PE 20080992A1
Authority
PE
Peru
Prior art keywords
heteroaryl
aryl
hepatitis
virus
serine protease
Prior art date
Application number
PE2007000815A
Other languages
English (en)
Inventor
Dequiang Niu
Donglei Liu
Joel D Moore
Gouyou Xu
Ying Sun
Datong Tang
Yat Sun Or
Zhe Wang
Yonghua Gai
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Publication of PE20080992A1 publication Critical patent/PE20080992A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

SE REFIERE A COMPUESTOS QUINOXALINIL MACROCICLICOS DE FORMULA (I), EN DONDE A ES H, -(C=O)-O-R1, -(C=O)-R2, -(C=O)-NH-R2, -S(O)2R1-, -S(O)2NHR2; R1 ES ARILO, HETEROARILO, ALQUILO(C1-C8), ENTRE OTROS; G ES -NHS(O)2-R3 O -NH(SO2)NR4R5; CADA R3 ES ARILO, HETEROARILO, ALQUILO, ALQUENILO(C1-C8), ENTRE OTROS; L ES -CH2-, -O-, -S- o -S(O)2-; X E Y TOMADOS JUNTO CON LOS CARBONO A LOS CUALES ESTAN UNIDOS FORMAN: ARILO, HETEROARILO, OPCIONALMENTE SUSTITUIDOS; W ESTA AUSENTE O ES -O-,-S-,-NH-, ALQUILENO(2-C4), ENTRE OTROS; Z ES H, -CN, -N3, HETEROARILO, ARILO, OPCIONALMENTE SUSTITUIDOS ENTRE OTROS; j ES DE 0 A 4; k ES DE 1 A 3; m ES DE 0 A 2. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCESO DE PREPARACION. ESTOS COMPUESTOS SON INHIBIDORES DE LA ACTIVIDAD DE SERINA PROTEASA, EN PARTICULAR LA PROTEASA NS3-NS4A DEL VIRUS DE LA HEPATITIS C (HCV), SIENDO UTILES EN EL TRATAMIENTO DE UNA INFECCION POR HCV
PE2007000815A 2006-06-26 2007-06-25 Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c PE20080992A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87244206P 2006-06-26 2006-06-26

Publications (1)

Publication Number Publication Date
PE20080992A1 true PE20080992A1 (es) 2008-08-06

Family

ID=38846474

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000815A PE20080992A1 (es) 2006-06-26 2007-06-25 Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c

Country Status (18)

Country Link
US (2) US8501681B2 (es)
EP (1) EP2066326A4 (es)
JP (1) JP5520046B2 (es)
KR (1) KR101505056B1 (es)
CN (1) CN101478970B (es)
AR (1) AR061629A1 (es)
AU (1) AU2007265157B2 (es)
BR (1) BRPI0714074A2 (es)
CA (1) CA2654945C (es)
IL (1) IL195512A (es)
MX (1) MX2008016528A (es)
NZ (1) NZ573275A (es)
PE (1) PE20080992A1 (es)
RU (1) RU2475494C2 (es)
TW (1) TWI454264B (es)
UY (1) UY30437A1 (es)
WO (1) WO2008002924A2 (es)
ZA (1) ZA200810519B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003007697A (ja) * 2001-06-21 2003-01-10 Hitachi Kokusai Electric Inc 半導体装置の製造方法、基板処理方法および基板処理装置
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
AU2006276246B2 (en) 2005-07-25 2012-09-27 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis C virus replication
UA93990C2 (ru) 2005-10-11 2011-03-25 Интермюн, Инк. Соединения и способ ингибирования репликации вируса гепатита c
KR20090024834A (ko) 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
JP5268927B2 (ja) 2006-10-27 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖｎｓ３プロテアーゼ阻害剤
EA200971041A1 (ru) 2007-05-10 2010-08-30 Интермьюн, Инк. Новые пептидные ингибиторы репликации вируса гепатита с
US20090005387A1 (en) * 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
WO2009005690A2 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
US8962551B2 (en) 2007-12-05 2015-02-24 Enanta Pharmaceuticals, Inc. Quinoxalinyl derivatives
WO2009073713A1 (en) * 2007-12-05 2009-06-11 Enanta Pharmaceuticals, Inc. Oximyl macrocyclic derivatives
EP2224920A4 (en) * 2007-12-06 2012-05-09 Enanta Pharm Inc PROCESS FOR THE PREPARATION OF MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS
CN102036966A (zh) * 2008-01-24 2011-04-27 益安药业 作为hcv丝氨酸蛋白酶抑制剂的二氟化三肽
US8003659B2 (en) 2008-02-04 2011-08-23 Indenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
CA2705300A1 (fr) * 2008-02-15 2009-06-04 Xeda International Macrocyclic inhibitors of hepatitis c protease
US8372802B2 (en) * 2008-03-20 2013-02-12 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis C virus inhibitors
KR20110005869A (ko) 2008-04-15 2011-01-19 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규한 마크로사이클릭 억제제
ES2491090T3 (es) 2008-07-22 2014-09-05 Merck Sharp & Dohme Corp. Combinaciones de un compuesto de quinoxalina macrocíclica que es un inhibidor de la proteasa NS3 del VHC con otros agentes del VHC
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) * 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
US8936781B2 (en) 2009-05-13 2015-01-20 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis C virus inhibitors
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
HUE030402T2 (en) * 2009-09-15 2017-05-29 Taigen Biotechnology Co Ltd HCV protease inhibitors
WO2011049908A2 (en) * 2009-10-19 2011-04-28 Enanta Pharmaceuticals, Inc. Bismacrokyclic compounds as hepatitis c virus inhibitors
JP2013511562A (ja) * 2009-11-24 2013-04-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎阻害化合物
MY156888A (en) * 2010-03-10 2016-04-15 Abbvie Bahamas Ltd Solid Compositions
WO2011150156A2 (en) * 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
CN103025736B (zh) * 2010-06-07 2016-07-06 Abbvie公司 大环的丙型肝炎丝氨酸蛋白酶抑制剂
NZ608720A (en) 2010-09-21 2015-03-27 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
US20120101032A1 (en) * 2010-10-22 2012-04-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
CN103534256B (zh) * 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
JP2014506255A (ja) * 2010-12-30 2014-03-13 エナンタ ファーマシューティカルズ インコーポレイテッド フェナントリジン大環状ｃ型肝炎セリンプロテアーゼ阻害剤
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN104136453B (zh) 2012-01-11 2018-01-12 艾伯维公司 用于制备hcv蛋白酶抑制剂的方法
AU2013329514A1 (en) 2012-10-08 2015-04-30 Abbvie Inc. Compounds useful for making HCV protease inhibitors
ES2613766T3 (es) 2012-10-19 2017-05-25 Bristol-Myers Squibb Company Derivados de carbamato de hexadecahidrociclopropa(e)pirrolo(1,2-a)(1,4)diazaciclopentadecinilo sustituidos con 9-metilo como inhibidores de la proteasa no estructural 3 (NS3) para el tratamiento de infecciones del virus de la hepatitis C
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
CN111689951A (zh) * 2020-06-11 2020-09-22 西北师范大学 一种1-苄基-3-烷基喹喔啉-2(1h)-酮的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
JP4352594B2 (ja) * 2000-03-15 2009-10-28 三菱マテリアル株式会社 酸化物イオン伝導体及びその製造方法並びにこれを用いた燃料電池
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
EP1590442A4 (en) * 2003-02-07 2007-07-18 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
WO2004094452A2 (en) 2003-04-16 2004-11-04 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
EP2143727B1 (en) * 2003-04-18 2015-01-21 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
PE20050431A1 (es) * 2003-09-22 2005-07-19 Boehringer Ingelheim Int Peptidos macrociclicos activos contra el virus de la hepatitis c
JP4525982B2 (ja) * 2003-09-26 2010-08-18 シェーリング コーポレイション Ｃ型肝炎ウイルスのｎｓ３セリンプロテアーゼの大環状インヒビター
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2007532479A (ja) * 2003-11-20 2007-11-15 シェーリング　コーポレイション Ｃ型肝炎ウイルスｎｓ３プロテアーゼの脱ペプチド化インヒビター
CA2549167A1 (en) * 2003-12-11 2005-06-30 Schering Corporation Inhibitors of hepatitis c virus ns3/ns4a serine protease
DE602005025855D1 (de) 2004-01-21 2011-02-24 Boehringer Ingelheim Pharma Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
CN101273038A (zh) 2005-07-29 2008-09-24 美迪维尔公司 丙型肝炎病毒的大环化合物抑制剂
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
US8501681B2 (en) 2013-08-06
JP2009541491A (ja) 2009-11-26
WO2008002924A3 (en) 2008-04-03
EP2066326A2 (en) 2009-06-10
TWI454264B (zh) 2014-10-01
TW200810777A (en) 2008-03-01
JP5520046B2 (ja) 2014-06-11
US8809264B2 (en) 2014-08-19
IL195512A0 (en) 2009-09-01
ZA200810519B (en) 2009-08-26
MX2008016528A (es) 2009-03-31
AU2007265157B2 (en) 2013-06-27
CN101478970B (zh) 2014-07-02
KR101505056B1 (ko) 2015-03-23
BRPI0714074A2 (pt) 2012-12-18
NZ573275A (en) 2011-12-22
CA2654945A1 (en) 2008-01-03
EP2066326A4 (en) 2010-09-29
AU2007265157A1 (en) 2008-01-03
AR061629A1 (es) 2008-09-10
US20080008681A1 (en) 2008-01-10
CN101478970A (zh) 2009-07-08
UY30437A1 (es) 2008-01-31
RU2475494C2 (ru) 2013-02-20
KR20090023732A (ko) 2009-03-05
US20070299078A1 (en) 2007-12-27
CA2654945C (en) 2013-08-06
WO2008002924A2 (en) 2008-01-03
IL195512A (en) 2014-05-28
RU2009102252A (ru) 2010-08-10

Similar Documents

Publication Publication Date Title
PE20080992A1 (es) Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c
PE20080539A1 (es) Piridazinonilos macrociclicos como inhibidores de serina proteasa de hepatitis c
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
EA201000201A1 (ru) Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
PE20121479A1 (es) Inhibidores del virus de la hepatitis c
PE20120666A1 (es) Inhibidores de los virus flaviviridae
NO20080879L (no) HCV-NS3-proteaseinhibitorer
ATE526341T1 (de) Makrozyklische verbindungen als antivirale mittel
CU23787B7 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
PE20070124A1 (es) Derivados de heteroaril para tratar virus
PE20080457A1 (es) Compuestos de oximilo macrociclico inhibidores de proteasas de hepatitis c
EA200701849A1 (ru) Пролекарственные соединения трициклических нуклеозидов, фармацевтическая композиция на их основе и способ лечения и/или ингибирования вирусной инфекции у млекопитающего
EA200700338A1 (ru) Ингибиторы рнк-зависимой рнк-полимеразы вируса гепатита с и композиции и способы лечения с их использованием
EA200802346A1 (ru) Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с
NO20052071L (no) Bezofuranforbindelser, preparater og metoder for behandling og forebygging av hepatitt C virale infeksjoner og relaterte sykdommer.
BRPI0415883A (pt) compostos e composições de nucleosìdeo para o tratamento de infecções virais
MY164469A (en) Hcv ns3 protease inhibitors
PE20071326A1 (es) Inhibidores de la polimerasa viral
PE20091841A1 (es) Inhibidores del virus de hepatitis c
GT200600262A (es) Uso de la sangliferina en el hcv (virus de la hepatitis "c")
PE20080355A1 (es) Compuestos peptidicos como inhibidores de proteasa de serina del virus de hepatitis c
PE20081312A1 (es) Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c
KR20240052708A (ko) 항바이러스제로서의 피롤리딘 주요 프로테아제 억제제
TH80266B (th) อนุพันธ์นิวคลีโอไซด์สำหรับการบำบัดการติดเชื้อไวรัสตับอักเสบ c

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration